Fundraising Fox
/People
Sign in

Gregg Fine

Founder

Chief Executive Officer at Stork Therapeutics

San Francisco, California, United States

FoundedStork Therapeutics

Find your path to Gregg

Sign up to see every warm intro you have to Gregg

  • Paths you didn't know you had: your email and LinkedIn already hold routes to Gregg. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

About

Gregg Fine is the Founder and CEO of Stork Therapeutics and a physician-scientist trained in adult hematology/oncology, with subspecialty training in clinical informatics and a clinical focus on thrombosis/coagulation and immunotherapy. His drug development experience spans late-stage research through first-in-human studies, NDA/MAA filings, and commercial launch, including IND filings, accelerated approval, breakthrough therapy designation, companion diagnostic development, and cell and gene therapy programs such as lipid nanoparticle mRNA neoantigen cancer vaccines, gene-edited TCR T cells, and CAR T therapies for solid and liquid tumors. He has served on executive leadership teams from seed stage through initial public offering and has supported Series A ($200M) and Series C ($75M) financings, with therapeutic experience in genitourinary oncology, melanoma, synov

Chief Executive Officer at Stork Therapeutics

Frequently asked questions

Who is Gregg Fine?
Gregg Fine is the Founder and CEO of Stork Therapeutics and a physician-scientist trained in adult hematology/oncology, with subspecialty training in clinical informatics and a clinical focus on thrombosis/coagulation and immunotherapy. His drug development experience spans late-stage research through first-in-human studies, NDA/MAA filings, and commercial launch, including IND filings, accelerated approval, breakthrough therapy designation, companion diagnostic development, and cell and gene therapy programs such as lipid nanoparticle mRNA neoantigen cancer vaccines, gene-edited TCR T cells, and CAR T therapies for solid and liquid tumors. He has served on executive leadership teams from seed stage through initial public offering and has supported Series A ($200M) and Series C ($75M) financings, with therapeutic experience in genitourinary oncology, melanoma, synov
Where does Gregg Fine work?
Gregg Fine is Chief Executive Officer of Stork Therapeutics.
What companies did Gregg Fine found?
Gregg Fine founded Stork Therapeutics.

Founder mafias

About this profile. Compiled from public sources — Stork Therapeutics's own website and public professional profiles — and summarised by Fundraising Fox; every fact is kept with where it came from. Spotted an error, or would rather not be listed? Email privacy@fundraisingfox.com · How we build profiles · Your rights